The achievement reflects Slade’s strengths in research and governance, demonstrating how evidence-based practice, strong clinical systems, and continuous improvement form the backbone of Slade’s services to hospital partners across Australia.
Icon Group oversees and supports the operations of Slade Pharmacy by providing services critical to the continuation of the organisation.
Across both conferences, Slade pharmacists showcased work that directly contributes to safer, more consistent and patient-centred pharmacy services.
From enhancing medication safety in cancer care and developing advanced digital tools, to improving antimicrobial reporting and strengthening transitions of care, each abstract highlights Slade’s commitment to delivering best-practice pharmacy services underpinned by robust governance.
The initiatives led and supported by Slade’s national Quality and Medication Safety Unit (QMSU), provide the frameworks, quality assurance programs, and education that enable the teams to deliver safe and high-quality care across metropolitan, regional, and private hospital settings.
Slade Health and Slade Pharmacy teams represented at the recent AdPha Conference
Head of QMSU, Claire Fitzgerald, said the contributions reflect Slade’s long-standing commitment to quality and the future of hospital pharmacy.
“Each abstract is a practical example of how strong governance and thoughtful innovation improve patient outcomes,” said Claire.
“This work not only informs our national frameworks but directly enhances the services we deliver to our hospital partners every day.”
As Slade celebrates six decades of excellence, the research achievements further demonstrate the legacy established in 1965: a commitment to integrity and exceptional patient care.
Slade Health was also represented at the AdPha conference, demonstrating the joint responsibility to drive consistent healthcare innovation.
CEO for Pharmacy and Compounding, Russell Hill said the milestone reinforces Slade’s role as a trusted partner in patient safety and medicine management.
“For 60 years, Slade has invested in clinical excellence and strong governance,” said Russell.
“These research contributions reflect the depth of expertise across our teams and our ongoing commitment to delivering the safest, most effective pharmacy services for hospitals nationwide.”
The presentations delivered at AdPha and COSA showcase Slade’s leadership in:
This work continues to shape the service models applied at Slade’s hospital sites, reinforcing their commitment to safe, evidence-based practice across Australia.
Explore Slade’s full collection of 2025 conference abstracts below.
Icon Group is Australia’s largest dedicated cancer care provider and has expanded globally into New Zealand, Asia and the United Kingdom.
People from across Icon Group share their stories of success, career progression and being iconic.
At Icon, you’ll help change lives, every single day. In return for your passion, dedication and agility, we offer a workplace where you can.
Read the latest news and updates across Icon Group.